Event Details

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

• Presentation Reference: PS-045
• Session: Parallel session: Hepatitis B and D: Emerging treatment options
• Date and Time: April 20, 2017 at 5:30 PM CET
• Authors: Man-Fung Yuen, et al.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

• Presentation Reference: THU-176
• Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
• Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
• Authors: Edward Gane, et al.

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients

• Presentation Reference: LBO-06
• Session: Late Breaker session
• Date and Time: April 22, 2017 at 5:15 PM CET
• Authors: Alice Turner, et al.